Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals is a biopharmaceutical company that focuses on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus on oncology. It has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.

Castor Maritime Inc

CEL-SCI

Marathon Oil

cbdMD Inc

Reddit stocks always make noise across social media platforms. But these investments have serious catalysts connected to them.

7 Reddit Stocks With Upcoming Catalysts To Watch

Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joe Turgeon on Q4 2020 Results - Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #earnings--Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.

Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation

Athenex

Bellus Health Inc

Catalyst Pharmaceuticals

New Age Beverages

OPKO Health

Uranium Energy

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

7 Penny Stocks That Wall Street Thinks Are Undervalued

The stock price of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) has increased by over 20% pre-market. This is why it happened.

SPPI Stock Price Increases Over 20% Pre-Market: Why It Happened

Spectrum Pharma is down due to two resolvable issues. If the Rolontis PDUFA issue is resolved, the stock may shoot up.

Spectrum Pharma Is Down But Not Out

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q3 2020 Results - Earnings Call Transcript

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Spectrum Pharmaceuticals (SPPI) Reports Q3 Loss, Misses Revenue Estimates

Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Spectrum Pharmaceuticals (SPPI) Jumps: Stock Rises 7%

Investors need to pay close attention to Spectrum (SPPI) stock based on the movements in the options market lately.

Implied Volatility Surging for Spectrum (SPPI) Stock Options

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2020 Results - Earnings Call Transcript

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 12.12% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Spectrum Pharmaceuticals (SPPI) Reports Q2 Loss, Lags Revenue Estimates

The company announced the pricing of a public offering of common stock.

Why Spectrum Pharmaceuticals Is Plunging Today

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) announced good news for cancer patients in its midstage trial on Tuesday.

Great News for Lung Cancer Patients in Spectrum’s Phase 2 Trial

Spectrum scores a key win in the clinic with its experimental lung cancer drug.

Why Spectrum Pharmaceuticals Stock Is on Fire Today

Xencor

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.

2 Top Cancer Treatment Stocks To Watch In July

Spectrum Pharma (SPPI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Spectrum Pharma (SPPI) Soars: Stock Adds 9.2% in Session

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Why Is Spectrum Pharma (SPPI) Up 6.6% Since Last Earnings Report?

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q1 Loss

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q1 2020 Results - Earnings Call Transcript

Spectrum Pharma (SPPI) Down 4.6% Since Last Earnings Report: Can It Rebound?

Shares jumped even though the company reported disappointing earnings. What can explain the boost?

News for Spectrum Pharma Stock (SPPI)